Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Stefan lutz Wollin"'
Autor:
Christina Hesse, Monika Niehof, Sebastian Konzok, Armin Braun, Olaf Pfennig, Jannie M.B. Sand, Peter Braubach, Danny Jonigk, Stefan lutz Wollin, Sarah Rønnow, Diana Julie Leeming, Mark P. Kühnel, Gregor Warnecke, Katherina Sewald, Hans-Gerd Fieguth
Publikováno v:
ILD/DPLD of known origin.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ccaeb1dbd35e0d486d10629e0c5dcd6
https://doi.org/10.1183/13993003.congress-2019.oa1609
https://doi.org/10.1183/13993003.congress-2019.oa1609
Autor:
Maela Duclos, Francisco Llamas Gutierrez, Laurent Vernhet, Bertrand De Latour, Audrey Joannes, Stéphane Jouneau, Claudie Morzadec, Nessrine Bellamri, Stefan-Lutz Wollin
Publikováno v:
European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2019, 54, ⟨10.1183/13993003.congress-2019.PA5373⟩
European Respiratory Journal, 2019, 54, ⟨10.1183/13993003.congress-2019.PA5373⟩
European Respiratory Journal, European Respiratory Society, 2019, 54, ⟨10.1183/13993003.congress-2019.PA5373⟩
European Respiratory Journal, 2019, 54, ⟨10.1183/13993003.congress-2019.PA5373⟩
Nintedanib and pirfenidone have been approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both drugs were shown to reduce but not to stop disease progression. Hence the medical need is still high for new effective anti-fibrotic molecule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4efbb6d840c0f8e311db2d2796ce0aca
https://doi.org/10.1183/13993003.congress-2019.pa5373
https://doi.org/10.1183/13993003.congress-2019.pa5373
Autor:
Andreas C. Hocke, Armin Braun, Heinz Fehrenbach, David J. Lamb, Wolfgang M. Kuebler, J Herbert, Martin Witzenrath, E Boiarina, Christoph Tabeling, Norbert Weissmann, Norbert Suttorp, Olga Danov, Katherina Sewald, Stefan-Lutz Wollin
Publikováno v:
Herbsttagung der Sektion Zellbiologie in der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13c1b6bb4ddf01c760800f627c9ec363
https://doi.org/10.1055/s-0039-1678408
https://doi.org/10.1055/s-0039-1678408
Autor:
Peter Braubach, Mark P. Kühnel, Danny Jonigk, Gregor Warnecke, Olaf Pfennig, Katherina Sewald, Monika Niehof, Stefan-Lutz Wollin, Samuel Mang, Hans-Gerd Fieguth, Christina Hesse, Armin Braun
Publikováno v:
Mechanisms of Lung Injury and Repair.
Pulmonary fibrosis comprises a multitude of rapidly progressing interstitial lung diseases assumed to develop from failure in the process of wound healing. Although TGFβ was reported to play a central role in the pathogenesis, it seems evident that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::755cdedabe87946dd852a618cfa32493
https://doi.org/10.1183/13993003.congress-2018.pa994
https://doi.org/10.1183/13993003.congress-2018.pa994
Autor:
Christoph Tabeling, Norbert Weissmann, Armin Braun, Katherina Sewald, Martin Witzenrath, WM Kübler, David J. Lamb, J Herbert, E Boiarina, Stefan-Lutz Wollin, Heinz Fehrenbach, Andreas C. Hocke, Norbert Suttorp
Einleitung: Syk ist eine intrazellulare Nicht-Rezeptor-Tyrosinkinase, die jüngst als zentraler Mediator glattmuskulärer Konstriktion identifiziert wurde. Ob Syk eine funktionelle Rolle in der pulmonalen Vasokonstriktion ausübt und sich hieraus mö
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb012d6cdee2ba14fcfb1b1bf62cc4f4
https://publica.fraunhofer.de/handle/publica/260638
https://publica.fraunhofer.de/handle/publica/260638
Autor:
E Boiarina, Wolfgang M. Kuebler, Armin Braun, Norbert Weissmann, Andreas C. Hocke, Martin Witzenrath, Christoph Tabeling, Norbert Suttorp, J Herbert, Stefan-Lutz Wollin, Heinz Fehrenbach, Katherina Sewald, David J. Lamb
Introduction: In the airways, spleen tyrosine kinase (Syk) promotes inflammation, smooth muscle cell proliferation and contraction (Tabeling, C. et al. Allergy 2017 Jul;72(7):1061-1072). However, little is known about the expression and role of Syk i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626fb2752b30fcb60c3f0d4414838abe
https://publica.fraunhofer.de/handle/publica/260640
https://publica.fraunhofer.de/handle/publica/260640
Autor:
Claudia Dallinger, Frank Hilberg, Stefan-Lutz Wollin, Rudolf Binder, Gerald Juergen Roth, Florian Colbatzky, Rozsa Schlenker-Herceg, Rolf Kaiser
Publikováno v:
Journal of Medicinal Chemistry. 58:1053-1063
Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db09e6596240ed07284fc1b313652e8b
https://doi.org/10.1021/jm501562a
https://doi.org/10.1021/jm501562a
Autor:
Christoph Tabeling, Marcus Maurer, JM Doehn, Stefan-Lutz Wollin, Andreas C. Hocke, Martin Witzenrath, Abdelilah S. Gounni, J. Scheffel, E Boiarina, David J. Lamb, J Herbert, Hesam Movassagh, Norbert Suttorp, Klaus J. Erb, Stefan Hippenstiel, Wolfgang M. Kuebler
Publikováno v:
Allergy. 72(7)
Background Spleen tyrosine kinase (Syk) is an intracellular non-receptor tyrosine kinase, which has been implicated as central immune modulator promoting allergic airway inflammation. Syk inhibition has been proposed as a new therapeutic approach in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b5ca9ff4879e9dca85d34eb9a039bfa
https://pubmed.ncbi.nlm.nih.gov/27906453
https://pubmed.ncbi.nlm.nih.gov/27906453
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: The long-acting β 2 -agonist (LABA) olodaterol was shown to have anti-fibrotic activity in primary human lung fibroblasts (Herrmann et al, Eur Respir J. 2014;44:Suppl.58) however, its anti-fibrotic in vivo efficacy has not yet been demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::face96a3c4b29930f775986683b6a18c
https://doi.org/10.1183/13993003.congress-2016.pa5056
https://doi.org/10.1183/13993003.congress-2016.pa5056
Autor:
Mary Sanville-Ross, Melissa Canfield, Gerhard Schaenzle, Bernd Guilliard, Eva Wex, Daniel Bischoff, Sylvia Blum, Don Souza, Andreas Schnapp, Mark Panzenbeck, Mohammed A. Kashem, Helena Obernolte, Oliver Radmacher, Della White, Georg Rast, Gerd-Michael Maier, Jennifer L Swantek, Olga Danov, Stefan lutz Wollin, Hannah Haas, Christine Strasser, Armin Braun, Katherina Sewald, Thierry Bouyssou, Klaus J. Erb, Takeshi Kono, Eva Thaler, Helga Nickel, Matthias Hoffmann, David J. Lamb
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 357(3)
BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrolidin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f14f89fa6cfeeec85a3fc0daa29eecf1
https://pubmed.ncbi.nlm.nih.gov/27048659
https://pubmed.ncbi.nlm.nih.gov/27048659